Clindamycin Phosphate Injection, Solution
Product Images NDC 43066-995

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Clindamycin Phosphate (NDC 43066-995). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Representative Container Lbl 43066-995-24 2-2 (Image 07)

FDA Label Image

Clindamycin In 5% Dextrose Structural Formula (Image 01)

Chemical structure of clindamycin phosphate, illustrating its molecular configuration with a pyrrolidine ring, phosphate group, and other characteristic functional groups.*

FDA Label Image

Representative Container Lbl 43066-993-24 1-2 (Image 02)

Clindamycin Injection USP in 5% Dextrose, 600 mg per 50 mL, single dose container for intravenous use. The label indicates the product is sterile, nonpyrogenic, and manufactured by Baxter Healthcare Corporation. The solution contains clindamycin phosphate and 5% dextrose as excipients.*

FDA Label Image

Representative Container Lbl 43066-993-24 2-2 (Image 03)

This image shows a label with a pink background containing the text 'BAR CODE POSITION ONLY' and a barcode number '34306993245' printed vertically. It is part of the packaging related to Clindamycin phosphate injection solution by Baxter Healthcare Corporation.*

FDA Label Image

Representative Carton Lbl 43066-993-24 1-2 (Image 04)

Clindamycin Injection USP in 5% Dextrose 600 mg per 50 mL intravenous injection solution. Pack contains 12 single-dose 50 mL containers. Manufactured by Baxter Healthcare Corporation. Label includes storage instructions to keep at 20° to 25°C (68° to 77°F) and avoid temperatures above 30°C.*

FDA Label Image

Representative Carton Lbl 43066-993-24 2-2 (Image 05)

This text panel provides detailed labeling for Clindamycin phosphate injection, 600 mg/50 mL, by Baxter Healthcare Corporation. It includes usage instructions indicating intravenous use only, warnings against rapid injection or intravenous push, ingredients per 50 mL, and cautions about supplementary medications and solution handling.*

FDA Label Image

Representative Container Lbl 43066-995-24 1-2 (Image 06)

Label for Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL intravenous injection solution. The label indicates a 50 mL single dose container by Baxter Healthcare Corporation. It includes storage instructions, caution notes, and trademark information for Galaxy and Novaplus.*

FDA Label Image

Representative Carton Lbl 43066-995-24 1-2 (Image 08)

Label for Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (18 mg/mL), injection solution for intravenous use. The label indicates the product is supplied in 12 single-dose 50 mL containers. Manufactured by Baxter Healthcare Corporation. Storage instructions specify 20° to 25°C with avoidance of temperatures above 30°C.*

FDA Label Image

Representative Carton Lbl 43066-995-24 2-2 (Image 09)

Prescribing information text panels for Clindamycin phosphate injection, solution, 900 mg/50 mL. Includes dosage form, intravenous route, composition details, cautions against rapid injection or series connections, and storage or clarity checks. Labeler is Baxter Healthcare Corporation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.